We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 22

Updates on international pricing issues for pharmaceutical and biologic products

  • Sidley Austin LLP
  • -
  • China, European Union, France, Germany, United Kingdom, USA
  • -
  • May 18 2012

Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies

Draft regulation on clinical trials - abolishment of obligatory insurance

  • Bird & Bird
  • -
  • European Union
  • -
  • February 25 2013

In July 2012 the European Commission published its proposal for a "Regulation on clinical trials on medicinal products for human use" (COM 2012 369

Commission targets Belgium on health insurance

  • McDermott Will & Emery
  • -
  • Belgium, European Union
  • -
  • May 9 2008

The European Commission has asked Belgium to amend its national rules to ensure that EU insurance directives are applied to private sickness funds when they offer complementary health insurance cover outside the scope of the mandatory social security requirements

Johnson & JohnsonNovartis another challenge to pay for delay: is this ever permissible?

  • Bryan Cave LLP
  • -
  • European Union, France, Germany, Italy, United Kingdom
  • -
  • January 14 2014

In the latest challenge to so-called “pay for delay” or “reverse payment” agreements, on 10 December 2013, the European Commission fined the

The Issues 2014 - upcoming legal topics in the Czech Republic

  • CMS Cameron McKenna
  • -
  • Czech Republic, European Union
  • -
  • January 24 2014

Since the summer, M&A practitioners across Europe have been talking about their ‘cautiously optimistic’ forecast for the markets. The first two

Commission authorises Irish health insurance tax and levies scheme

  • McDermott Will & Emery
  • -
  • European Union, Ireland
  • -
  • June 26 2009

The European Commission has approved a new Irish health insurance scheme that includes both levies and tax-relief measures designed to decrease the risk differentials for health insurers between old and young customers

Indemnity arrangements for healthcare professionals: long overdue

  • Kennedys Law LLP
  • -
  • European Union, United Kingdom
  • -
  • July 26 2013

The Department of Health's consultation on the implementation of the Health Care and Associated Professions (Indemnity Arrangements) Order 2013 (the

Global corporate insurance & regulatory bulletin

  • Mayer Brown JSM
  • -
  • China, European Union, United Kingdom, USA
  • -
  • December 5 2013

The China Insurance Regulatory Commission (“CIRC”) announced new rules (Implementing Rules of Provisional Measures on Outbound Investments with

EU Commission proposes expansion to anti-discrimination rules with consequences for health insurers

  • Norton Rose Fulbright LLP
  • -
  • European Union
  • -
  • July 22 2008

On 2 July 2008 the EU Commission issued a draft directive on implementing the principle of equal treatment between persons irrespective of religion or belief, disability, age or sexual orientation

Canada-Europe Free Trade Agreement: a new prescription for drug patents in Canada

  • Davis LLP
  • -
  • Canada, European Union
  • -
  • October 31 2013

On October 17, Canadian Prime Minister Stephen Harper flew to Brussels to conclude a Comprehensive Economic and Trade Agreement ("CETA"), or free